Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 4/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16973697 | 0.98 | GNAI3 (0.42) | GNAI3GNAO1GNAI1KDM1ADCPS | |
| Hydrochloric Acid SCHEMBL1700029 | 0.98 | GNAI3 (0.42) | GNAI3GNAO1GNAI1KDM1ADCPS | |
| Trifluoroacetic Acid SCHEMBL17025592 | 0.87 | KDM1A (0.39) | KDM1AHPGDSPARP1PARP2 | |
| SCHEMBL22789404 | 0.86 | KDM1A (0.33) | GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL20992134 | 0.86 | KDM1A (0.33) | GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL13740262 | 0.86 | KDM1A (0.33) | GNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL17095988 | 0.82 | GNAI3 (0.41) | GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL17096046 | 0.82 | GNAI3 (0.41) | GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL17729337 | 0.79 | GNAI3 (0.43) | GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL20160685 | 0.78 | KDM1A (0.39) | KDM1ADCPSHPGDSJAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | claimed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | claimed |
| JP-2005514365-A | — | — | 2005-05-19 | — | — | JP | claimed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025076441-A1 | COMPOUNDS OF GCN2 MODULATORS | Alesta Therapeutics BV (NL) | 2025-04-10 | — | — | WO | disclosed |
| EP-4472974-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| US-6150557-A | REACTING COMPOUND CONTAINING SECONDARY AMIDE GROUPS WITH BENZENESULFINIC ACID OR ITS DERIVATIVE IN PRESENCE OF ACID CATALYST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-21 | — | — | US | disclosed |
| US-6103936-A | REACTING ALDEHYDE, SULFIDE, SULFONE, OR SULFOXIDE WITH FORMAMIDE IN PRESENCE OF ACID CATALYST, AND OPTIONALLY A DEHYDRATING AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| US-5969184-A | INTERMEDIATES FOR COMPOUNDS WHICH CONTROL PRODUCTION OF EXCESSIVE INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | GNAI3 1498/4885GNAO1 2649/4885GNAI1 1457/4885 |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | GNAI3 618/4885GNAO1 117/4885GNAI1 485/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | GNAI3 835/4885GNAO1 764/4885GNAI1 618/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | GNAI3 1353/4885GNAO1 2313/4885GNAI1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.